Aurinia Pharmaceuticals (AUPH) traded lower on Wednesday as RBC Capital Markets downgraded the stock, citing an uneven risk-reward profile after the biotech added over ~8% in the previous session in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback